Synergistic suppression of cholangiocarcinoma cells via DNA damage response and cell cycle arrest by dual targeting PARP and ATM in DNA damage repair pathway
Open Access
- 15 June 2025
- journal article
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 189, 118273
Abstract
No abstract availableKeywords
Funding Information
- Naval Medical Research Command (MOH-000248\u201300)
- Agency for Science, Technology and Research (SD GMC ( DDC/FY2023/EX/79-A117, H23G1a0009)
- Khon Kaen University (NSRF)
- Ministry of Education, Ethiopia (FY2024-MOET1\u20130002)
- Japan Agency for Medical Research and Development (236B9008)
This publication has 40 references indexed in Scilit:
- Targeting the ATM pathway in cancer: Opportunities, challenges and personalized therapeutic strategiesCancer Treatment Reviews, 2024
- Dual blockage of PI3K-mTOR and FGFR induced autophagic cell death in cholangiocarcinoma cellsHeliyon, 2024
- Clinical treatment of cholangiocarcinoma: an updated comprehensive reviewAnnals of Hepatology, 2022
- SynergyFinder Plus: Toward Better Interpretation and Annotation of Drug Combination Screening DatasetsGenomics, Proteomics & Bioinformatics, 2022
- Inhibiting homologous recombination by targeting RAD51 proteinBiochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2021
- Practical considerations in screening for genetic alterations in cholangiocarcinomaAnnals of Oncology, 2021
- An Overview of PARP Inhibitors for the Treatment of Breast CancerTargeted Oncology, 2021
- ROS and the DNA damage response in cancerRedox Biology, 2019
- ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor OlaparibTranslational Oncology, 2017
- Genomic and Epigenomic Alterations in CancerThe American Journal of Pathology, 2016